(LFSC) F/m Emerald Life Sciences - Ratings and Ratios
Exchange: US • Country: USA • Currency: USD • Type: Etf • • Health
The fund is an actively managed exchange-traded fund ('ETF') and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund's investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
Additional Sources for LFSC ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LFSC ETF Overview
| Market Cap in USD | 49m |
| Category | Health |
| IPO / Inception | 2024-10-30 |
LFSC ETF Ratings
| Growth 5y | -7.08% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | 141 |
| Analysts | - |
| Fair Price Momentum | 22.16 USD |
| Fair Price DCF | - |
LFSC Dividends
No Dividends PaidLFSC Growth Ratios
| Growth Correlation 3m | -58% |
| Growth Correlation 12m | -58% |
| Growth Correlation 5y | -58% |
| CAGR 5y | 0.88% |
| CAGR/Mean DD 5y | 0.13 |
| Sharpe Ratio 12m | -0.18 |
| Alpha | -41.03 |
| Beta | 1.68 |
| Volatility | 29.67% |
| Current Volume | 0.9k |
| Average Volume 20d | 1.3k |
What is the price of LFSC stocks?
As of January 23, 2025, the stock is trading at USD 25.22 with a total of 900 shares traded.
Over the past week, the price has changed by +3.12%, over one month by +6.24%, over three months by +0.88% and over the past year by +0.88%.
As of January 23, 2025, the stock is trading at USD 25.22 with a total of 900 shares traded.
Over the past week, the price has changed by +3.12%, over one month by +6.24%, over three months by +0.88% and over the past year by +0.88%.
Is F/m Emerald Life Sciences a good stock to buy?
Neither. Based on ValueRay Analyses, F/m Emerald Life Sciences is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -7.08 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LFSC as of January 2025 is 22.16. This means that LFSC is currently overvalued and has a potential downside of -12.13%.
Neither. Based on ValueRay Analyses, F/m Emerald Life Sciences is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -7.08 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LFSC as of January 2025 is 22.16. This means that LFSC is currently overvalued and has a potential downside of -12.13%.
Is LFSC a buy, sell or hold?
F/m Emerald Life Sciences has no consensus analysts rating.
F/m Emerald Life Sciences has no consensus analysts rating.
What are the forecast for LFSC stock price target?
According to ValueRays Forecast Model, LFSC F/m Emerald Life Sciences will be worth about 25.2 in January 2026. The stock is currently trading at 25.22. This means that the stock has a potential downside of -0.12%.
According to ValueRays Forecast Model, LFSC F/m Emerald Life Sciences will be worth about 25.2 in January 2026. The stock is currently trading at 25.22. This means that the stock has a potential downside of -0.12%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 25.2 | -0.1% |